Advanced Accelerator Applications S.A.

General Information
We are an innovative radiopharmaceutical company that develops, produces and commercializes MNM products. MNM is a medical specialty that uses trace amounts of radioactive compounds to treat diseases such as cancer and create functional images of organs and lesions. Our lead therapeutic product candidate, Lutathera, is a novel MNM compound that we are currently developing for the treatment of NETs, a significant unmet medical need. Lutathera is a Lu-177 labeled somatostatin analogue peptide that has received orphan drug designation from the EMA and FDA.
Employees: 368
Founded: 2002
Contact Information
Address 20 rue Diesel, 01630 Saint Genis Pouilly, France
Phone Number +33 (0) 4 50 99 30 70
Web Address HTTP://
View Prospectus: Advanced Accelerator Applications S.A.
Financial Information
Market Cap $617.1mil
Revenues $86.6 mil (last 12 months)
Net Income $-17.8 mil (last 12 months)
IPO Profile
Symbol AAAP
Exchange NASDAQ
Shares (millions): 4.7
Price range $16.00 - $16.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Citigroup/ Jefferies​ ​
CO-Managers Canaccord Genuity​/ JMP Securities​ ​
Expected To Trade: 11/11/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change